The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Low-dose metronomic oral cyclophosphamide plus prednisone for castration resistant prostate cancer (CRPC): A retrospective study.
Nieves Martinez Lago
No relevant relationships to disclose
Urbano Anido Herranz
No relevant relationships to disclose
Luis Leon Mateos
No relevant relationships to disclose
Maria Vieito
No relevant relationships to disclose
Rafael Varela Ponte
No relevant relationships to disclose
Santiago Aguin Losada
No relevant relationships to disclose
Elena Brozos Vazquez
No relevant relationships to disclose
Marta Carmona Campos
No relevant relationships to disclose
Carmela Rodriguez Lopez
No relevant relationships to disclose
Alexandra Sabela Cortegoso mosquera
No relevant relationships to disclose
Sonia Candamio Folgar
No relevant relationships to disclose
Rafael López López
No relevant relationships to disclose